Skip to main content
. 2022 Mar 7;10(3):e004054. doi: 10.1136/jitc-2021-004054

Figure 2.

Figure 2

BR105 blocks CD47 binding to various SIRPα variants. (A, B) Blocking soluble CD47 binding to human SIRPα variants (V1, V2 and V8) was assessed by competition ELISA assay. Inhibiting of CD47 binding to SIRPα-expressing U937 (C) or macrophages (D) by BR105 was determined by flow cytometry analysis. Data represent mean ± SEM; representative of n=3 is shown. *indicate statistical differences compared with the respective isotype control group: **p<0.01.